FIELD: pharmacology.
SUBSTANCE: composition is described comprising a pharmaceutically acceptable carrier and a purified monoclonal antibody comprising a heavy chain variable domain comprising CDR1, CDR2 and CDR3 and a light chain variable domain comprising CDR1, CDR2 and CDR3, wherein the monoclonal antibody specifically binds to protein A (SpA) Staphylococcus aureus with KD less than 1×10-10 M through its Fab site paratope. The monoclonal antibody is able to displace human IgG immunoglobulins associated with SpA on the surface of Staphylococcus aureus bacteria through their Fc regions.
EFFECT: significant level of protection against lethal infection with Staphylococcus aureus strain.
8 cl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING INFECTIONS CAUSED BY STAPHYLOCOCCUS AUREUS | 2015 |
|
RU2764981C1 |
| ANTIBODIES AGAINST PD-1 AND THEIR USE | 2018 |
|
RU2788616C2 |
| COMBINATIONS OF ANTIBODIES TO STAPHYLOCOCCUS AUREUS | 2019 |
|
RU2804815C2 |
| ANTIBODIES AGAINST STAPHYLOCOCCUS AUREUS LEUKOTOXINS | 2019 |
|
RU2805969C2 |
| ANTIBODIES FOR SPECIFIC BINDING OF STAPHYLOCOCCUS AUREUS ALPHA-TOXIN AND METHODS OF APPLICATION | 2012 |
|
RU2620065C2 |
| ANTIBODIES AGAINST CD40 AND THEIR USE | 2018 |
|
RU2796413C2 |
| STAPHYLOCOCCUS AUREUS CLUMPING FACTOR A (ClfA) ANTIBODY | 2019 |
|
RU2818805C2 |
| ANTI-LIGAND 1 ANTIBODY OF PROGRAMMED CELL DEATH (PD-L1), ITS ANTIGEN-BINDING FRAGMENT AND THEIR MEDICAL APPLICATION | 2016 |
|
RU2727914C2 |
| METHODS OF TREATING S. AUREUS-ASSOCIATED DISEASES | 2013 |
|
RU2661406C2 |
| ANTIBODY AGAINST LAG-3, ITS ANTIGEN-BINDING FRAGMENT AND THEIR PHARMACEUTICAL APPLICATION | 2017 |
|
RU2757813C2 |
